Trial · NCT01593254
Adverse events363
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 363
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Arm 1: Imatinib | 20 | 86 | |
| other | Anaemia | Blood and lymphatic system disorders | Arm 2: Dasatinib | 53 | 171 | |
| other | Anaemia | Blood and lymphatic system disorders | Dasatinib After Crossover From Imatinib | 15 | 46 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm 1: Imatinib | 8 | 86 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm 2: Dasatinib | 17 | 171 | |
| other | Leukopenia | Blood and lymphatic system disorders | Dasatinib After Crossover From Imatinib | 8 | 46 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm 1: Imatinib | 20 | 86 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm 2: Dasatinib | 42 | 171 | |
| other | Neutropenia | Blood and lymphatic system disorders | Dasatinib After Crossover From Imatinib | 20 | 46 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm 1: Imatinib | 12 | 86 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm 2: Dasatinib | 40 | 171 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Dasatinib After Crossover From Imatinib | 10 | 46 | |
| other | Pericardial effusion | Cardiac disorders | Arm 1: Imatinib | 0 | 86 | |
| other | Pericardial effusion | Cardiac disorders | Arm 2: Dasatinib | 9 | 171 | |
| other | Pericardial effusion | Cardiac disorders | Dasatinib After Crossover From Imatinib | 4 | 46 | |
| other | Eyelid oedema | Eye disorders | Arm 1: Imatinib | 8 | 86 | |
| other | Eyelid oedema | Eye disorders | Arm 2: Dasatinib | 4 | 171 | |
| other | Eyelid oedema | Eye disorders | Dasatinib After Crossover From Imatinib | 1 | 46 | |
| other | Abdominal pain | Gastrointestinal disorders | Arm 1: Imatinib | 3 | 86 | |
| other | Abdominal pain | Gastrointestinal disorders | Arm 2: Dasatinib | 12 | 171 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01593254/events